In human Burkitt's Lymphoma (BL) BRG cells, a t(8;14) translocation, placing c-myc near the Em enhancer of the H chain locus, causes tumor expansion. Earlier, we showed that a peptide nucleic acid complementary to the Em sequence (PNAEm), specifically inhibited the expression of translocated c-myc and impaired the growth of BRG cells-induced subcutaneous tumors in mice suffering from severe combined immunodeficiency (SCID). In this study, the therapeutic potential of PNAEm was evaluated in a systemic mouse model. BRG-BL cells transfected with the luciferase gene were inoculated intravenously into SCID mice resulting in a preferential expansion, similar to the one of human adult patients, in the abdominal cavity, central nervous system and bone marrow. The mice were chronically injected intraperitoneally either with PNAEm or with control PNA. The treatment was stopped when the control animals developed severe neurological symptoms. As detected both by inspection at necropsy and imaging, overall tumor growth in PNAEm-treated mice decreased by 480%. Histological and immunohistochemical studies showed, only in PNAEm-treated mice, a substantially reduced BL cell growth at the major sites of invasion and vast areas of necrosis in the lymphomatous tissues, with concomitant c-myc expression downregulation. Altogether, the data support the therapeutic potential of PNAEm in human adult BL.
Introduction
Burkitt's Lymphoma (BL) cells are often characterized by chromosomal translocations of the c-myc oncogene leading to its upregulation and overexpression. 1, 2 The abundance of intracellular MYC protein leads to active cell proliferation, propensity to apoptosis and acquisition of transformed properties. [3] [4] [5] Owing to its central role in cell transformation, the inhibition of c-myc expression in BL cells could, therefore, result in partial or total loss of their transformed properties. This issue has been the subject of investigation in our laboratory, using specific peptide nucleic acids (PNAs). 6, 7 Peptide nucleic acids are synthetic nucleic acid analogs 8 resistant to nucleases and proteases, and with high affinity and specificity to the complementary DNA or RNA. 8 PNAs can cross the nuclear membrane when linked to an appropriate nuclear localization sequence (NLS) 9, 10 and inhibit transcription of the targeted gene(s). Two PNAs were designed to inhibit c-myc transcription, one complementary to the second exon of c-myc (PNAmyc), 10 the other with specificity for the Em enhancer located within the Ig heavy chain locus on chromosome 14 (PNAEm). 6 In many BL cells, the Em enhancer is juxtaposed by t (8;14) chromosomal translocation to c-myc, determining the oncogene hyperexpression. PNAEm, on binding to Em, can block c-myc upregulation and consequent BL cell hyperproliferation. Both PNAs inhibited c-myc RNA transcription and MYC protein expression with equal efficiency, but PNAEm was eventually selected for further experiments, because of its ability to specifically inhibit the expression of the translocated c-myc and not the normal allele. 6 In a preliminary approach to an in vivo model system, we used severe combined immunodeficient (SCID) mice injected subcutaneously with BL cells, which progressed to form subcutaneous tumor masses, and a number of pharmacokinetic parameters for PNAEm were also evaluated, including tissue distribution and persistence of the active core portion with time. 11 In particular, we determined that the therapeutically active portion of PNA persisted in tumor tissues for a prolonged time after administration, and that the compound did not exhibit acute toxicity even after chronic injection at the highest possible dose.
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By these preliminary data, PNAEm seemed as a possibly suitable therapeutic agent for BL in vivo. However, the efficacy of PNAEm needs to be tested in an animal model, in which BL cells expansion involves the major sites of BL cells seen in human adult patients with an aggressive sporadic form often associated with HIV (human immunodeficiency virus) in the Western world and malaria in the Central African countries (for example, peritoneal fat, meningeal tissues and bone marrow). 12, 13 Here, we present evidence supporting the notion that this latter form of the disease can be significantly inhibited by PNAEm.
Materials and methods

PNA synthesis
A unique PNA complementary to the 3 0 -5 0 strand of the Em core sequence (PNAEm wt GenBank accession no. X00253.1, bases 136-157: GCAGGAAGCAGGTCA CCG-NLS) (EPO application IT 07018695) and its matching mutated PNA (PNAEm mut GTAGGAAGTA GGTCATCG-NLS) were synthesized as described earlier. 6 Cell culture, retroviral infection and selection The BL cell line, BRG, was obtained and maintained in culture as described earlier.
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The retroviral luciferase vector was obtained by cloning the firefly luciferase gene into the retroviral pLXIN bicistronic vector (Clontech, Mountain View, CA 94043), to obtain pL-Luc-IN. Retroviruses were prepared by calcium phosphate transient transfection of HEK293 T cells, after mixing with 5 mg of pkat2ampac 14 and 5 mg of pL-Luc-IN. The retrovirus-containing supernatant was collected 48 h post-transfection and used to infect BRG cells. After 48 h, the transduced cells were selected in the presence of 2 mg ml À1 G418, (Calbiochem, San Diego, CA, 92121). The resulting cells were denominated BRG-BL-Luc, and presented phenotypic characteristics and in vitro growth properties virtually identical to the parental BRG-BL line 7 (data not shown). To test the effect of PNAEm wt/mut treatment, in two repeat experiments, groups of five animals inoculated intravenously with BRG-Luc were injected intraperitoneally with PNAEm wt or PNAEm mut (both 0.2 mM in 100 ml of phosphate buffered saline) starting 1 week after the inoculation. The treatment was continued with chronic injections every other day for 4 weeks and daily for the subsequent 4 days. At the time of injection, the mice were also monitored for variations in weight and basic health parameters.
In vivo BL cell imaging Bioluminescent imaging was carried out with a highly sensitive CCD camera mounted in light-tight specimen box (IVIS, Xenogen 100 imaging system; Xenogen, Alameda, CA). Mice were injected intraperitoneally (150 mg kg À1 in phosphate buffered saline) with DLuciferin (Biosynth International Inc., Naperville, IL), and anesthetized with 1-3% isofluorane. A maximum of five mice were then placed in the supine position on the stage inside the camera box with continuous exposure to isofluorane. Imaging gives a linear response in photons/ second for exposure times ranging from 1 to 5 min. A colorimetric coded reference bar, from purple: minimum to red: maximum, allows a 'first glance' intensity quantization of the luminescence. Bioluminescent signals from BRG-BL-Luc cells, as detected by the camera system were recorded, integrated, digitalized, displayed and quantified (in photons/second) using the Living Image (Xenogen) software. 15 Tumor cells growth in the PNAEm wt or PNAEm mut -treated groups was calculated (photons/seconds ± s.d.) by measuring the luminescence emitted in each mouse by the BRG-Luc cells, during tumorigenesis at increasing times and number of treatments, with 2.5 min of exposure and with a homogeneous sensitivity setting.
Morphological and immunohistochemical tissue analysis
At the end of the experiments, the mice were killed in a saturated CO 2 chamber and necropsies were carried out. Organs and tumors were fixed in formalin and then embedded in paraffin as described earlier.
Morphology was evaluated by microscopic analysis after hematoxylin and eosin staining. Immunohistochemical analysis of MYC expression was carried out using 9E11 Clone of NCL-c-MYC mAb for human c-myc (Novocastra, Newcastle, UK) as described earlier.
7 BL cells were identified by their positivity to the CD20 antibody 16 (clone L26-Ventana Medical System. IllkirchCedex, France) and cell proliferation index by the Mib-1/ ki-67 17 (clone 30.9-Ventana).
Statistical data analysis Standard deviations were calculated by using the Excel program, whereas the significance of the difference of the mean luminescence of PNAEm wt or PNAEm mut -treated mice was determined by the SPSS 16.0 statistical software (SPSS Inc., Chicago, IL). The P-value was calculated both by the t-test and by the Mann-Whitney test.
Results and discussion
Inhibition of BL cells growth in SCID mice as detected by chemoluminescence
The optimal dosage of the BL cells to be inoculated was calculated by treating groups of five mice with increasing cell numbers (1 Â 10 5 , 2Â 10 5 and 4 Â 10 5 cells per mouse) and by measuring the luminescence of each image, with increasing exposure times at days 7, 14, 21, 28 and 35. From these experiments (Figure 1 ), 2 Â 10 5 cells per mouse was determined to be the optimal dose capable of inducing tumors, as they were already detectable at day 7 and were consistent for site and time of appearance in different experiments. The inoculum of lower cell numbers induced a non-homogeneous tumor growth, whereas higher cell numbers produced luminescent signals exceeding the linear range, particularly at late time points (Figure 1) .
On the basis of the results of the preliminary tests, two groups of five mice were inoculated with 2 Â 10 5 cells per mouse. After 7 days, when BL cell growth was detectable by bioluminescence (Figure 2a) , each group received the first intraperitoneal treatment consisting of PNAEm wt or of PNAEm mut as control. Treatments were repeated every other day for 4 weeks and daily for the subsequent 4 days (till day 33). BRG-BL-Luc cell growth was monitored as described in Materials and methods.
Figures 2a and b report the results of one typical test. The growth curves for tumors in mice receiving PNAEm wt or PNAEm mut began to differ both by the t-test (Po0.04) and by the Mann-Whitney test (Po0.08) already at day 14. At day 30, the difference was significant (Po0.038/ 0.016), and at day 33, the growth slope of BL cells in PNAEm wt and PNAEm mut -treated mice diverged sharply (Po0.009/0.008). The mathematical analysis of the data determined that, at the final time point, the overall tumor burden was reduced by 86% in PNAEm wt -treated mice (Figure 2b) .
Serial bioluminescence images of the first of the two experiments, in which groups of five mice were chronically injected with PNAEm mut or with PNAEm wt are shown in Figure 2a . The images of mice at day 7 and at day 14 after BRG-BL-Luc injection (corresponding to PNAEm wt/mut , first and second treatment) showed a rather weak signal corresponding to the initial BL cell infiltration (Figure 2b) . At day 21, BL cell growth signals appeared to be localized mainly in the abdomen and were more widespread in the PNAEm mut than in the PNAEm wttreated mice. At day 28, this pattern became more clearly defined. At day 30, the luminescent signal extended to areas of the central nervous system and the neurological symptoms were clearly detectable in the control mice, but were still absent in the PNAEm wt -treated mice. At day 33, the images of the infiltrated area in the control mice lost definition, because of the high luminescence of tumor cells. At this stage, because of worsening neurological symptoms of PNAEm mut -treated mice, so severe as to predict certain short-term death, the experiment had to be stopped. All mice were killed, including the PNAEm wt -treated one that showed only minor neurological symptoms.
Effects of PNAEm mut and PNAEm wt determined at necropsy
The extent of BL cell infiltration was investigated by systematic macroscopic inspection at necropsy (Table 1 , columns 1 & 4), as confirmed by low magnification microscopy in Figure 3 . The major infiltration sites were the rachis, abdominal fat and brain. The rachis, which was thickened and grossly infiltrated in the control mice, appeared much less altered in the PNAEm wt -treated animals; likewise, the brain was swollen and exhibited loss of gyri in the control mice, but appeared almost normal in the PNAEm wt -treated animals. Finally, the abdominal fat, which was expanded and occupied most of the abdominal cavity in the control mice because of gross infiltration, appeared virtually normal in quantity and morphology in the PNAEm wt -treated animals (Figure 3c ).
Microscopic examination revealed additional relevant details. Lymphomatous tissue distribution was similar in both the PNAEm wt -treated and control mice, although infiltration was lower in the former group. A subjective evaluation of the degree of infiltration and inhibition by PNAEm wt is provided in Table 1 . For example, in the brain, lymphoma growth was observed primarily in meningeal tissue. However, although a thick layer of lymphoma cells was present in the control mice, this layer was generally much thinner and discontinuous at many sites in the PNAEm wt -treated animals ( Figure 3a) . Likewise, the structural features of the abdominal fat were affected by a heavy lymphomatous infiltration in the control mice, whereas large areas of tumor-free adipose tissue could still be observed in the PNAEm wt -treated mice (Figure 3b) . Finally, after microscopic examination, infiltration sites were observed in the rachis (Figure 3c) , particularly in the meningeal tissue and in the bone marrow. These data, which are included in ) at increasing exposure times (1.0, 2.5, 5.0 min) are shown at various time points after inoculation. At days 7 and 14, cell growth was barely detectable unless subjected to long exposure times; at day 21, a low signal of BL cell growth started to localize in the abdomen and in the central nervous system (CNS); at day 28, this pattern was more defined and localized in the CNS and abdomen; finally, at day 35, tumor cell proliferation lost definition, because of high luminescence of the tumor cell mass. (b) Analysis with the appropriate software of the data in panel (a) as average total luminescence per time point per mice ± s.d. calculated by Excel program.
PNAEl: cytocidal, cytostatic for disseminated BL S Matis et al Table 1 , (columns 2 & 5), also underline the importance and extent of the bone marrow infiltration, which, similar to that at meningeal level, was inhibited by treatment with PNAEm wt .
Large areas of necrosis were typically present in BL tumor tissue from the PNAEm wt -treated, but not in the control mice (Table 1, columns 3 & 6; Figures 4a and e) . Cells at boundaries of necrotic areas displayed nuclear changes, including shrinkage, increased basophilia and karyorrhexis. Furthermore, abnormal nuclei intermingled with coagulated non-nucleated eosinophilic cells were predominant near to the center of necrotic areas (Figure 4e) . Collectively, the above findings indicate that two mechanisms possibly operated in the PNAEm wttreated animals to prevent tumor spreading. One was represented by the block of cell proliferation caused by c-myc downregulation and the other by cell lysis, which probably occurred after the c-myc downregulation, and resulted in growth arrest (Figures 4c, d, g and h) . Indeed, earlier in vitro observations showed that the inhibition of c-myc expression by PNAEm wt is followed by growth arrest of the proliferating BL cells and concomitant apoptosis inhibition. 6 In these conditions, some of the cells undergo terminal plasma cell differentiation (manuscript in preparation), whereas the majority die by necrosis. In connection with this, it is of note that marked differences between the patterns of c-myc expression in BL cells from treated and control animals were observed by immunohistochemical c-myc staining. Thus, although in the control animals BL cells exhibited a robust c-myc staining (Figure 4c ), in the PNAEm wt -treated mice, the c-myc-positive cells were observed mostly in the surroundings of the necrotic areas and their staining intensity was much weaker (left side Figure 4h ). This comparative weakening of c-myc signal is not confined to the necrotic area, but is detectable in the surrounding, still apparently viable, CD20-positive BL cells of the PNAEm wt -treated mice (Figures 4b and f) . A similar trend of the B-cell proliferation decrease is apparent as from the signal of the cell cycle marker, mib-1/ki67 (Figures 4d and h ).
In conclusion, PNAEm wt proved capable of consistently reducing the tumor burden in SCID mice inoculated with human BL cells. Such reduction was likely caused by two synergic mechanisms: (i)-inhibition of cell growth because of decreased intracellular c-myc level 7 and (ii) growth arrest and necrosis of the cells that had already expanded in vivo. These inhibitory mechanisms were also operating in the central nervous system and bone marrow, two sites which are relatively frequent targets for BL expansion in the human disease. 12, 13 As chemotherapy is often unable to clear neoplastic cells from these sites, PNA could represent an effective gene therapy or, more likely, a valid complementary therapeutic alternative to the traditional protocols. Figure 4 Immunohistochemistry of PNA Em mut and PNAEm wttreated mice. High magnification analysis ( Â 400) of brain tissue from mice receiving different treatments, as indicated, is stained by hematoxylin and eosin (panel a and e). The BL cells, characterized by their CD20 positivity, infiltrating the brain meningeal tissues exhibit vast areas of necrosis in the PNAEm wt -treated mice (f). These areas are absent in tissues from PNAEm mut -treated mice (b). Not only necrotic cells, but also viable cells, infiltrating meningeal tissues exhibit lower c-myc levels after PNAEm wt treatment (g) compared with the matching control (c). This trend is similar to the decrease in cell proliferation as detectable by Mib-1/ki67 immunohistochemical staining induced by PNAEm wt (h), but not by PNAEm mut (d).
